Search the Studies

70 Studies found from all possible combinations of your search terms. Select a protocol that you wish to review.
Protocol Number Title Protocol Status Min-Max Age Institute Keywords
000715-CHBiorepository in Participants Who Undergo OTC for Gonadotoxic TherapyParticipants currently recruited/enrolled4-35 YearsNICHDOvarian Failure
000106-CHGonadal Tissue Freezing for Fertility Preservation in Individuals at risk for Ovarian Dysfunction and Premature Ovarian InsufficiencyParticipants currently recruited/enrolled4-21 YearsNICHDPremature Ovarian
001109-CDefining the Natural History of Squamous Cell Carcinoma in Fanconi AnemiaParticipants currently recruited/enrolled8-125 YearsNCI Failure
001099-CA Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-Fusion Molecule, in Subjects with Unresectable, Locally Advanced, or Metastatic Solid Tumors thatParticipants currently recruited/enrolled18-125 YearsNCI Ovarian
001004-CA Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon Oncosignature (R) StatusParticipants currently recruited/enrolled18-120 YearsNCI Ovarian
000977-IPhase I/II Study using Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease with an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined with Cytokine (IL-6, +/- IFN-gamma) AntagonistsParticipants currently recruited/enrolled4-65 YearsNIAIDFailure
000954-CA Phase 1/2 Single Arm Open-Label Clinical Trial of TC-510 In Patients with Advanced Mesothelin-Expressing CancerParticipants currently recruited/enrolled18-125 YearsNCI Ovarian
000783-CPhase I/Ib Trial Evaluating the Safety and Efficacy of BET Inhibitor, ZEN003694 with PD-1 Inhibitor, Nivolumab with or without CTLA-4 Inhibitor, Ipilumumab in Solid TumorsParticipants currently recruited/enrolled18-125 YearsNCI Ovarian
000682-ARThe Role of Anifrolumab in Improving Markers of Vascular Risk in Patients with Systemic Lupus ErythematosusRecruitment has not started18-80 YearsNIAMSPremature
000567-CPhase 1 Trial of Gemcitabine Combined with the BAY 1895344 ATR Inhibitor with Expansion Cohorts in Advanced Pancreatic and Ovarian CancerParticipants currently recruited/enrolled18-125 YearsNCI Ovarian
000484-CRandomized Phase II Trial of Durvalumab (D) plus Olaparib (O) and Cediranib (C: DOC) Compared to OC or DC or Chemotherapy in Platinum-Resistant Recurrent Ovarian Cancer with Prior BevacizumabParticipants currently recruited/enrolled18-125 YearsNCI Ovarian
000387-HThe Natural History of Acquired and Inherited Bone Marrow Failure Syndromes.Participants currently recruited/enrolled2-125 YearsNHLBIFailure
000343-HDetection of T cell Somatic Mutations in Bone Marrow Failure Using Whole Exome or Targeted SequencingEnrolling by Invitation18-125 YearsNHLBIFailure
000299-HTechnical Development of Cardiovascular MRIParticipants currently recruited/enrolled18-125 YearsNHLBIFailure
000237-CPhase II Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis from Colorectal, Appendiceal, Small Bowel, Gastric, Ovarian, or Other Gynecologic Primary CancerParticipants currently recruited/enrolled18-125 YearsNCI Ovarian
000206-CHEndometrial Basis for Infertility in Women with Recurrent Implantation Failure and Pregnancy LossParticipants currently recruited/enrolled18-42 YearsNICHDFailure
21-C-0012Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis from Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma HistologiesParticipants currently recruited/enrolled18-125 YearsNCI Ovarian
20-I-0123A Longitudinal Study of COVID-19 Sequelae and ImmunityParticipants currently recruited/enrolled18-125 YearsNIAIDFailure
20-C-0098A Phase 1/2, Open Label, Dose-Escalation, Safety and Tolerability Study of NC410 in Subjects with Advanced or Metastatic Solid TumorsCompleted Study; data analyses ongoing18-125 YearsNCI Ovarian
20-C-0013Phase I/II Trial of PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell CancersNo longer recruiting/follow-up only18-125 YearsNCI Ovarian
19-H-0088NHLBI DIR Transcatheter Mitral Cerclage Annuloplasty Early Feasibility StudyNo longer recruiting/follow-up only21-99 YearsNHLBIFailure
19-C-0143A Phase II Study Using the Administration of Autologous T-Cells Engineered using the Sleeping Beauty Transposon/Transposase System to Express T-Cell Receptors Reactive Against Mutated Neoantigens in Patients with Metastatic CancerParticipants currently recruited/enrolled18-70 YearsNCI Ovarian
19-C-0117A Phase 1 / 2 Single Arm Open-label Clinical Trial of Gavocabtagene Autoleucel (gavo-cel) in Patients with Advanced Mesothelin Expressing CancerParticipants currently recruited/enrolled18-120 YearsNCI Ovarian
19-C-0025Tissue Acquisition and Genomics Analysis of Breast Cancer and Other Gynecologic MalignanciesEnrolling by Invitation18-125 YearsNCI Ovarian
18-N-0140Clinical Laboratory Evaluation of Chronic Autonomic FailureParticipants currently recruited/enrolled18-125 YearsNINDSFailure
18-C-0143A Phase 1 Study of Intraperitoneal MCY-M11 Therapy for Women with Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects with Peritoneal Mesothelioma with Recurrence after Prior ChemotherapyCompleted Study; data analyses ongoing18-125 YearsNCI Ovarian
18-C-0049A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in Patients with Metastatic CancerParticipants currently recruited/enrolled18-72 YearsNCI Ovarian
17-H-0124Peripheral Blood Stem Cell Collection for Sickle Cell Disease (SCD) Patients Using PlerixaforCompleted Study; data analyses ongoing18-125 YearsNHLBIFailure
17-C-0100Collection of Malignant Ascites, Pleural Fluid and Blood from Patients with Solid TumorsNo longer recruiting/follow-up only18-125 YearsNCI Ovarian
17-C-0011Phase 1 Study of Intraperitoneal Infusion of Autologous Monocytes with Sylatron (Peginterferon alfa-2b) and Actimmune (Interferon gamma-1b) in Women with Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal CancerCompleted Study; data analyses ongoing18-125 YearsNCI Ovarian
16-C-0131A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced with a CD70-Binding Chimeric Antigen Receptor to Patients with CD70-Expressing CancersParticipants currently recruited/enrolled18-70 YearsNCI Ovarian
16-C-0128A Phase I/II Study of Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination with Nab-Paclitaxel in Participants with Previously Treated Metastatic and/ or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid TumorsCompleted Study; data analyses ongoing18-125 YearsNCI Ovarian
16-C-0088A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary PeritoneaCompleted Study; data analyses ongoing18-125 YearsNCI Ovarian
16-C-0073A Phase 2 Study of Olaparib and Cediranib for the Treatment of Recurrent Ovarian CancerCompleted Study; data analyses ongoing18-125 YearsNCI Ovarian
15-C-0150A Phase I/II Trial of Topotecan with VX-970 (M6620), an ATR Kinase Inhibitor in Small Cell CancersNo longer recruiting/follow-up only18-125 YearsNCI Ovarian
15-C-0145Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody Durvalumab (MEDI4736) in Combination with Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal CancersParticipants currently recruited/enrolled18-125 YearsNCI Ovarian
14-I-0009Characterization and Management of Patients with HIV-1 Infection Who Experience Virologic Failure Despite Combination Antiretroviral TherapyCompleted Study; data analyses ongoing18-100 YearsNIAIDFailure
14-H-0077Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia in Individuals with Higher Risk of Transplant FailureParticipants currently recruited/enrolled4-125 YearsNHLBIFailure
14-C-0156A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) In BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, and High Grade Serous Ovarian CancerCompleted Study; data analyses ongoing18-125 YearsNCI Ovarian
14-C-0056Collection of Blood from Patients with Ovarian, Primary Peritoneal or Fallopian Tube CancerCompleted Study; data analyses ongoing18-125 YearsNCI Ovarian
14-C-0015Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA MutationsCompleted Study; data analyses ongoing18-125 YearsNCI Ovarian
13-H-0060Analysis of Samples Collected from a Subject who Received ACP- 501 (Human Recombinant Lecithin:Cholesterol Acyltransferase [rhLCAT])Completed Study; data analyses ongoing18-100 YearsNHLBIFailure
13-C-0202Tissue Procurement and Natural History Study of Patients with Malignant Mesothelioma and Other Mesothelin Expressing CancersParticipants currently recruited/enrolled2-125 YearsNCI Ovarian
13-C-0131Inpatient Hospice with Procurement of Tissue on Expiration in Thoracic Malignancies, Bladder Cancer, Ovarian Cancer, Epithelial Cancer and Patients Treated with an Adoptive Cellular TherapyParticipants currently recruited/enrolled18-125 YearsNCI Ovarian
13-C-0119Evaluation of Local Response of Prostate Cancer to Irradiation Using Multiparametric MRI and MR-Guided BiopsiesParticipants currently recruited/enrolled18-125 YearsNCI Failure
13-C-0118A Phase I/II Trial of TRC102 (methoxyamine HCl) in Combination with Temozolomide in Patients with Relapsed Solid Tumors and LymphomasParticipants currently recruited/enrolled18-125 YearsNCI Ovarian
12-C-0205A Phase II Study of Cabozantinib (XL184) in Patients With Advanced/Metastatic Urothelial CarcinomaCompleted Study; data analyses ongoing18-125 YearsNCI Ovarian
12-C-0081Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast CancerNo longer recruiting/follow-up only18-125 YearsNCI Ovarian
11-H-0134A Pilot Study of a Thrombopoietin-Receptor Agonist (TPO-R Agonist), Eltrombopag, in Moderate Aplastic Anemia PatientsNo longer recruiting/follow-up only2-125 YearsNHLBIFailure
11-C-0242Collection of Blood from Patients with Cancer, Other Tumors, or Tumor Predisposition Syndromes for Analysis of Genetic Differences in Drug DispositionParticipants currently recruited/enrolled3-125 YearsNCI Ovarian
11-C-0140A Phase I Study of Gemcitabine, Carboplatin and Lenalidomide (GCL) for Treatment of Patients with Advanced/Metastatic Urothelial Carcinoma (UC) and Other Solid TumorsCompleted Study; data analyses ongoing18-125 YearsNCI Ovarian
11-C-0061Phase I Trial of Z-Endoxifen in Adults with Refractory Hormone Receptor-Positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or other Hormone Receptor-Positive Solid TumorsNo longer recruiting/follow-up only18-125 YearsNCI Ovarian
11-C-0034DICER1-Related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History StudyParticipants currently recruited/enrolled0-125 YearsNCI Ovarian
11-C-0033Extended Follow-up of High Ovarian Cancer Risk Cohort from 02C0268 (GOG-199)Completed Study; data analyses ongoing18-100 YearsNCI Ovarian
10-H-0154Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused with a Reduced Dose of Non-Mobilized Donor T-CellsParticipants currently recruited/enrolled4-80 YearsNHLBIFailure
10-C-0166A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in Metastatic Cancers Plus the Administration of PembrolizumabParticipants currently recruited/enrolled18-72 YearsNCI Ovarian
09-N-0010Biomarkers of Risk of Parkinson DiseaseCompleted Study; data analyses ongoing18-70 YearsNINDSFailure
07-H-0113Procurement and Analysis of Blood, Bone Marrow, and Buccal Mucosa Samples from Healthy Volunteers to Support Clinical and Translational Research Projects in the NHLBIParticipants currently recruited/enrolled8-125 YearsNHLBIFailure
04-HG-0127Clinical and Basic Investigations of Methylmalonic Acidemia (MMA) and Related DisordersParticipants currently recruited/enrolled0-125 YearsNHGRIFailure
04-H-0012Collection of Blood, Bone Marrow, Urine, and/or Tissue Samples from Patients with Solid Tumors, Hematological Malignancies or Non-Malignant Hematologic Disorders or HLA Compatible Family MembersParticipants currently recruited/enrolled2-125 YearsNHLBIFailure
04-C-0232A Multi-Institutional Study of Proteomic Evaluation of Epithelial Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer Patients in First Clinical Remission: Development of a Protein Fingerprint Profile of RelapseCompleted Study; data analyses ongoing18-125 YearsNCI Ovarian
02-DK-0022Long-Term Efficacy of Leptin Replacement in Treatment of LipodystrophyCompleted Study; data analyses ongoing1-125 YearsNIDDKOvarian
02-C-0268Prospective Study of Prophylactic Salpingo-Oophorectomy and Longitudinal CA-125 Screening Among Women at Increased Genetic Risk of Ovarian CancerCompleted Study; data analyses ongoing19-100 YearsNCI Ovarian
02-C-0212Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian CancerCompleted Study; data analyses ongoing18-100 YearsNCI Ovarian
02-C-0052Etiologic Investigation of Cancer Susceptibility in Inherited Bone Marrow Failure Syndromes: A Natural History StudyParticipants currently recruited/enrolled0-125 YearsNCI Failure
01-C-0009Breast Imaging Screening Studies in Women at High Genetic Risk of Breast Cancer: Annual Follow-up StudyCompleted Study; data analyses ongoing18-100 YearsNCI Ovarian
00-DK-0107Search for Novel Methods to Detect Acute Renal FailureParticipants currently recruited/enrolled3-125 YearsNIDDKFailure
98-CH-0081Clinical and Basic Investigations into Smith-Lemli-Opitz SyndromeCompleted Study; data analyses ongoing0-125 YearsNICHDFailure
96-C-0071Follow-up for Patients Previously Enrolled on the Center for Cancer Research ProtocolsNo longer recruiting/follow-up only0-125 YearsNCI Ovarian
78-HG-0093Use of Cysteamine in the Treatment of CystinosisParticipants currently recruited/enrolled0-125 YearsNHGRIFailure
10 Center Drive,Bethesda, MD 20892 | Directions
Privacy Statement | Accessibility | Plain Language | FOIA | Disclaimer
Clinical Center | National Institutes of Health | HHS Vulnerability Disclosure | U.S. Department of Health and Human Services | USA.gov
NIH…Turning Discovery Into Health®